Solid Biosciences Inc.
SLDB
$2.70
$0.031.12%
| Weiss Ratings | SLDB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | SLDB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | SLDB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.97 | |||
| Price History | SLDB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -26.83% | |||
| 30-Day Total Return | -51.70% | |||
| 60-Day Total Return | -14.01% | |||
| 90-Day Total Return | -52.63% | |||
| Year to Date Total Return | -30.77% | |||
| 1-Year Total Return | -74.67% | |||
| 2-Year Total Return | -44.10% | |||
| 3-Year Total Return | -83.18% | |||
| 5-Year Total Return | -92.59% | |||
| 52-Week High % Change | -76.33% | |||
| 52-Week Low % Change | 7.88% | |||
| Price | SLDB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $11.28 | |||
| 52-Week Low Price | $2.48 | |||
| 52-Week Low Price (Date) | Apr 09, 2025 | |||
| 52-Week High Price (Date) | Apr 11, 2024 | |||
| Valuation | SLDB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 206.91M | |||
| Enterprise Value | 82.16M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.04 | |||
| Earnings Per Share Growth | -37.24% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.79 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $2.70 | |||
| Enterprise Value/EBITDA (TTM) | -0.65 | |||
| Enterprise Value/EBIT | -0.63 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | SLDB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 42.71M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | SLDB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 337 4680 | |||
| Address | 500 Rutherford Avenue Charlestown, MA 02129 | |||
| Website | www.solidbio.com | |||
| Country | United States | |||
| Year Founded | 2013 | |||
| Profitability | SLDB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | SLDB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -45.86% | |||
| Return on Equity | -- | |||
| Income Statement | SLDB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -96.43M | |||
| EBITDA (TTM) | -127.27M | |||
| EBIT (TTM) | -129.73M | |||
| Net Income (TTM) | -124.70M | |||
| Net Income Avl. to Common (TTM) | -124.70M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -109.47% | |||
| EPS Diluted (TTM) | -3.04 | |||
| EPS Diluted Growth (Q YOY) | 0.76% | |||
| Balance Sheet | SLDB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 148.92M | |||
| Cash Per Share (Q) | $3.49 | |||
| Total Current Assets (Q) | 157.30M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 137.25M | |||
| Current Ratio (Q) | 5.199 | |||
| Book Value Per Share (Q) | $3.39 | |||
| Total Assets (Q) | 188.66M | |||
| Total Current Liabilities (Q) | 30.26M | |||
| Total Debt (Q) | 24.18M | |||
| Total Liabilities (Q) | 51.42M | |||
| Total Common Equity (Q) | 137.25M | |||
| Cash Flow | SLDB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -16.09M | |||
| Cash from Financing (TTM) | 122.44M | |||
| Net Change in Cash (TTM) | 6.34M | |||
| Levered Free Cash Flow (TTM) | -56.21M | |||
| Cash from Operations (TTM) | -100.01M | |||
